|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 208.9 USD | +3.18% |
|
+7.47% | -19.27% |
| Apr. 26 | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
| Apr. 25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
Feb 23 (Reuters) - EMA:
* EMA SAYS NEW TREATMENT FOR RARE MOTOR NEURONE DISEASE RECOMMENDED FOR APPROVAL
* EMA: RECOMMENDED GRANTING MARKETING AUTHORISATION FOR A NEW THERAPY TO TREAT ADULT PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)
* EMA SAYS QALSODY (TOFERSEN) INDICATED FOR TREATMENT OF ADULTS WITH ALS, WHO HAVE MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE Source text for Eikon: Further company coverage: [ ] (Reuters.Briefs@thomsonreuters.com)
| 1st Jan change | Capi. | |
|---|---|---|
| -19.27% | 30.42B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B | |
| +2.29% | 7.72B |
BIOGEN INC. 
